Prof. Peter Ka-Fung Chiu is currently an Associate Professor at the Chinese University of Hong Kong. He is also the principal investigator of the SMART trial, a multicentre randomized controlled trial comparing MRI prostate pathway and extended transperineal prostate biopsy pathway in the diagnosis of significant prostate cancer. He is also leading a study on using biomarkers and MRI for prostate cancer screening in Hong Kong as part of the CUHK Jockey Club multi-cancer screening program. He has primary interests in prostate cancer and benign prostatic hyperplasia. For prostate cancer, he has conducted studies in novel diagnostic modalities including blood biomarker prostate health index (phi), urine biomarker spermine, and transperineal MRI-Ultrasound fusion biopsy.